Categories
Latest Industry Intelligence
Precision medicine uses information about an individual’s genes, proteins, and environment to prevent, diagnose, and [...]
In January 2022, DDW’s Megan Thomas spoke to decision-makers from the drug discovery industry about [...]
Gesynta Pharma has announced that an IND (Investigational New Drug Application) has been submitted to the U.S. Food & Drug Administration (FDA) for its oral drug candidate GS-248 in patients with systemic sclerosis. Concurrently, more than half of the patients in the ongoing Phase II study in four countries across Europe have been recruited. The […]
Menu ≡ ╳ 
